Competition ( Novartis with deep pockets ) looms large and hangs over smal biotechs .
It's hard to see that (must your charts are helping you, LOL)!
You missed this part of the article:
"it should be emphasized that eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."
The author of the article, Zach Hartman is PhD (biochemistry and molecular biology) and a very decent and intelligent observer of the biotech scene. When you leave out relevant information from the article, you undermine your argument (among other things).
An additional note: I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product! How can I know this WITHOUT charts? Easy, look at the available data (as opposed to black magic).
News 
Market Data 
Discover 
